A-Route "ByroCure Preparing Phase 1b Clinical Trial for Liver Metastasis Cancer Treatment... Dosing to Complete Within the Year"

[Asia Economy Reporter Hyunseok Yoo] Virocure, invested by A-Route, announced on the 12th that it has successfully completed the Phase 1a clinical trial of the liver metastasis cancer treatment 'RC402-IT' in Australia and is preparing for Phase 1b.

In Phase 1b, Virocure plans to verify not only safety but also some efficacy through combination therapy with the global big pharma Merck's immuno-oncology drug 'Keytruda.' Virocure's clinical team is currently discussing candidate hospitals and patient recruitment groups with the Australian Contract Research Organization (CRO).

Virocure aims to decide the target cancer types and number of patients to recruit and enter Phase 1b clinical trials for the liver metastasis cancer treatment around September. They plan to complete the administration of the treatment to recruited patients for Phase 1b by the end of this year and finish all Phase 1 trials within the first quarter of next year.

A Virocure official stated, "We are currently closely reviewing the detailed data from Phase 1a and discussing the specifics required for proceeding with Phase 1b with the CRO. RC402 is a virus proven to be safe for humans and has an excellent priming effect that enhances the anti-cancer immune system, so we expect good results in Phase 1b, which focuses on combination therapy with immuno-oncology drugs."

Recently, Virocure successfully completed Phase 1a clinical trials in Australia involving solid cancer patients, administering 'RC402-IT' alone and in combination with the immuno-oncology drug 'Keytruda.' It was confirmed that no dose-limiting toxicity (DLT) occurred in any patient group up to the planned maximum dose in Phase 1a. Among them, in the terminal colorectal cancer patient group, no further cancer progression was observed.

In addition to the liver metastasis cancer treatment, Virocure holds a pipeline of four virus-based anticancer drugs: ▲ oral virus anticancer drug using reovirus (RC402-PO), ▲ intravenous solid cancer treatment using modified reovirus (RP116-IV), and ▲ solid cancer treatment through myxoma virus gene recombination (MC 509N).

Virocure is also developing a coronavirus vaccine platform based on reovirus. As part of a support program receiving annual subsidies from the Canadian government foundation, joint development is underway with the University of Ottawa in Canada.

This content was produced with the assistance of AI translation services.